C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin. The API was listed for its potential to reduce the symptoms of COVID-19 in combination with other anti-viral drugs based on initial research in South Korea and India.   Digoxin is extracted from the digitalis lanata plant and due to the structure of the ingredient, it cannot be manu...